Concepedia

David Surguladze

DS

Statistics

Publications

22

Citations

1.2K

H-Index

17

Active since

2006

Affiliations

Eli Lilly (United States)(Current)

New York Proton Center

Janssen (Belgium)

Johnson & Johnson (United States)

Memorial Sloan Kettering Cancer Center

David Surguladze is an author at Eli Lilly (United States) specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2006–2021

22

Publications

22

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

, , +17

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

David Schaer, Sandaruwan Geeganage, Nelusha Amaladas et al. · Clinical Cancer Research · 2019 · 127 citations

, , +17

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio et al. · Clinical Cancer Research · 2010 · 124 citations · Full text

, , +17

Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines

Xiaohu Ouyang, Evgueni L. Piatnitski, Vatee Pattaropong et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 99 citations

, , +16

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Helen Kotanides, Yiwen Li, Maria Malabunga et al. · Cancer Immunology Research · 2020 · 68 citations

, , +17

1–5 of 22